Tags

Type your tag names separated by a space and hit enter

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
Neurology. 2007 Aug 14; 69(7):631-9.Neur

Abstract

BACKGROUND

Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Abeta(42) as biomarkers of the dementia or prodromal stages of AD, we are unaware of any study to evaluate these potential CSF biomarkers of latent AD.

METHODS

We determined the ratio of CSF tau/Abeta(42) (T/Abeta) using Luminex reagents in 129 control individuals that spanned from 21 to 100 years of age; for comparison we included patients with MCI (n = 12), probable AD (n = 21), or other neurodegenerative diseases (n = 12).

RESULTS

We identified 16% of the control group with abnormally elevated CSF T/Abeta; all were 53 years or older. Using age-matched controls with normal CSF T/Abeta we showed that the high CSF T/Abeta subgroup of controls had significantly increased frequency of the epsilon4 allele of the apolipoprotein E gene and significantly increased risk of conversion to MCI during follow-up of up to 42 months suggesting that they had latent AD at the time of lumbar puncture.

CONCLUSIONS

These generally applicable methods establish cutoff values to identify control individuals at increased risk of conversion to mild cognitive impairment which may be useful to people weighing the risk-benefit ratio of new preventive therapeutics and to researchers striving to enrich clinical trial populations with people with latent Alzheimer disease.

Authors+Show Affiliations

Mental Illness Research, Education, and Clinical Center and Department of Psychiatry, VA Puget Sound Health Care System, University of Washington, Seattle, WA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17698783

Citation

Li, G, et al. "CSF tau/Abeta42 Ratio for Increased Risk of Mild Cognitive Impairment: a Follow-up Study." Neurology, vol. 69, no. 7, 2007, pp. 631-9.
Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631-9.
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., & Montine, T. J. (2007). CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology, 69(7), 631-9.
Li G, et al. CSF tau/Abeta42 Ratio for Increased Risk of Mild Cognitive Impairment: a Follow-up Study. Neurology. 2007 Aug 14;69(7):631-9. PubMed PMID: 17698783.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. AU - Li,G, AU - Sokal,I, AU - Quinn,J F, AU - Leverenz,J B, AU - Brodey,M, AU - Schellenberg,G D, AU - Kaye,J A, AU - Raskind,M A, AU - Zhang,J, AU - Peskind,E R, AU - Montine,T J, PY - 2007/8/19/pubmed PY - 2007/9/5/medline PY - 2007/8/19/entrez SP - 631 EP - 9 JF - Neurology JO - Neurology VL - 69 IS - 7 N2 - BACKGROUND: Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Abeta(42) as biomarkers of the dementia or prodromal stages of AD, we are unaware of any study to evaluate these potential CSF biomarkers of latent AD. METHODS: We determined the ratio of CSF tau/Abeta(42) (T/Abeta) using Luminex reagents in 129 control individuals that spanned from 21 to 100 years of age; for comparison we included patients with MCI (n = 12), probable AD (n = 21), or other neurodegenerative diseases (n = 12). RESULTS: We identified 16% of the control group with abnormally elevated CSF T/Abeta; all were 53 years or older. Using age-matched controls with normal CSF T/Abeta we showed that the high CSF T/Abeta subgroup of controls had significantly increased frequency of the epsilon4 allele of the apolipoprotein E gene and significantly increased risk of conversion to MCI during follow-up of up to 42 months suggesting that they had latent AD at the time of lumbar puncture. CONCLUSIONS: These generally applicable methods establish cutoff values to identify control individuals at increased risk of conversion to mild cognitive impairment which may be useful to people weighing the risk-benefit ratio of new preventive therapeutics and to researchers striving to enrich clinical trial populations with people with latent Alzheimer disease. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/17698783/CSF_tau/Abeta42_ratio_for_increased_risk_of_mild_cognitive_impairment:_a_follow_up_study_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=17698783 DB - PRIME DP - Unbound Medicine ER -